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MBoC | ARTICLE

Effects of anchor structure and glycosylation
of Fcγ receptor III on ligand binding affinity
Ning Jianga,†,‡, Wei Chenb,†,§, Prithiviraj Jothikumara, Jaina M. Patelc,
Rangaiah Shashidharamurthyc,∥, Periasamy Selvarajc, and Cheng Zhua,b,*
a
Coulter Department of Biomedical Engineering and bWoodruff School of Mechanical Engineering, Georgia Institute
of Technology, Atlanta, GA 30332; cDepartment of Pathology and Laboratory Medicine, Emory University, Atlanta,
GA 30322

ABSTRACT Isoforms of the Fcγ receptor III (FcγRIII or CD16) are cell surface receptors for the
Fc portion of IgG and important regulators of humoral immune responses. Different ligand
binding kinetics of FcγRIII isoforms are obtained in three dimensions by surface plasmon resonance and in two dimensions by a micropipette adhesion frequency assay. We show that the
anchor structure of CD16 isoforms isolated from the cell membrane affects their binding affinities in a ligand-specific manner. Changing the receptor anchor structure from full to partial
to none decreases the ligand binding affinity for human IgG1 (hIgG1) but increases it for murine IgG2a (mIgG2a). Removing N-glycosylation from the CD16 protein core by tunicamycin
also increases the ligand binding affinity. Molecular dynamics simulations indicate that deglycosylation at Asn-163 of CD16 removes the steric hindrance for the CD16-hIgG1 Fc binding
and thus increases the binding affinity. These results highlight an unexpected sensitivity of ligand binding to the receptor anchor structure and glycosylation and suggest their respective
roles in controlling allosterically the conformation of the ligand binding pocket of CD16.
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INTRODUCTION
In humans, type III cell surface receptors for the Fc portion of immunoglobulin (Ig) G (Fcγ receptor III or CD16) are encoded by two
genes, A and B, which give two protein products, CD16a and
CD16b, respectively (Kimberly et al., 2002; Nimmerjahn and
Ravetch, 2008). CD16a is expressed on macrophages, mast cells,
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and natural killer cells as a transmembrane receptor (Ravetch
and Perussia, 1989; Selvaraj et al., 1989). Expressed exclusively on
neutrophils, CD16b is the only Fc receptor (FcR) anchored by a glycosyl-phosphatidylinositol (GPI) linker to the plasma membrane
(Selvaraj et al., 1988). CD16b is polymorphic, with two alleles—neutrophil alloantigen 1 (NA1) and 2 (NA2). Despite the lack of a signaling component, CD16b plays an active role in triggering Ca2+ mobilization and neutrophil degranulation (Kimberly et al., 1990; Unkeless
et al., 1995). Furthermore, in conjunction with FcγRIIa (CD32a),
CD16b activates phagocytosis, degranulation, and oxidative burst,
which lead to clearance of opsonized pathogens by neutrophils.
Moreover, soluble forms of CD16 containing the Ig-like extracellular
domains of the receptor circulate in plasma (Teillaud et al., 1994).
CD16 are highly glycosylated molecules, with five (CD16a), four
(CD16bNA1), or six (CD16bNA2) N-glycosylation sites on their extracellular domains (Figure 1). CD16a on NK cells has a higher affinity
for ligands than on monocytes due to differential cell type–specific
glycosylation (high mannose– and complex-type oligosaccharides
for NK cell CD16a but not monocyte CD16a), despite their identical protein cores (Edberg and Kimberly, 1997). Single-residue replacements of the four N-glycosylation sites (Asn-39, Asn-75, Asn163, and Asn-170) of CD16bNA1 show that the N163Q mutant
binds monomeric IgG with higher affinity than the other mutants
(Drescher et al., 2003). In addition, preincubation of wild-type
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CD16bNA1-transfected cells with tunicamycin (an inhibitor of
N-glycosylation) results in increased binding of monomeric IgG,
whereas the same treatment of cells transfected with N163Q
mutant of CD16bNA1 has no effect. These results suggest that
glycosylation at Asn-163, which is shared by all three CD16
membrane isoforms and located in the ligand binding pocket
(Sondermann et al., 2000; Radaev et al., 2001; Ferrara et al.,
2011), regulates the affinity of CD16 for IgG (Drescher et al.,
2003). However, the extent to which the glycosylation affects the
ligand binding affinity and kinetics has not been quantified. The
structural basis for the glycosylation effects also has not been
elucidated.
The cocrystal structures of CD16bNA2 and CD16a in complex
with an Fc fragment of human IgG1 (hFc1) have been independently
solved by several groups (Sondermann et al., 2000; Radaev et al.,
2001; Ferrara et al., 2011). Although the crystals obtained have different space group symmetries, the structures are almost identical,
showing a 1:1 stoichiometry for binding. CD16 adopts the characteristic heart-shaped domain arrangement as described for soluble
FcγRIIb and other soluble FcRs. Compared with the standalone
structure, CD16 further opens its interdomain angle by 10° when it
is liganded with hFc1. Concurrently, hFc1 opens asymmetrically
upon complex formation, upon which both CH2 domains bend
away from the C2 axis of the homodimeric hFc1, but one CH2 domain is dislocated more than the other.
Ligand binding kinetics of CD16 has been studied using surface
plasma resonance (SPR; Galon et al., 1997; Maenaka et al., 2001; Li
et al., 2007). In SPR, one binding partner is immobilized onto a sensor surface over which the other binding partner flows in a fluidic
phase to interact in three dimensions. Soluble aglycosylated
CD16NA2 produced by Escherichia coli used in two studies yielded
drastically different kinetic rates (Galon et al., 1997; Maenaka et al.,
2001), despite the fact that the respective materials from the two

groups produced the same crystal structure (Sondermann et al.,
2000; Radaev et al., 2001). One group also compared glycosylated
with aglycosylated CD16bNA2 and showed that they have similar
binding affinity for human IgG1 (hIgG1; Galon et al., 1997). The
similarity in three-dimensional (3D) affinity is at odds with the observation that the glycosylation of CD16 greatly affects its ligand binding (Edberg and Kimberly, 1997; Drescher et al., 2003).
Ligand binding of CD16 triggers signaling and effector functions
such as phagocytosis and antibody-dependent cellular cytotoxicity
(Nagarajan et al., 1995b). Cell surface CD16 binds small immune
complex in three dimensions and IgG-opsonized surfaces in two dimensions (Nagarajan et al., 1995b). Ligand binding kinetics of CD16
has also been measured in two dimensions by micropipette adhesion assay, which analyzes receptor–ligand interactions across the
junctional gap between two apposing surfaces (Chesla et al., 1998,
2000; Williams et al., 2000a,b, 2001; Shashidharamurthy et al.,
2009). This assay can examine effects of membrane organization
and cellular environment of the interacting molecules that cannot
be addressed by SPR. The differences between two-dimensional
(2D) and 3D binding have been highlighted by studies of binding of
T-cell receptors (TCRs) and coreceptors with peptide-major histocompatibility complex (pMHC) molecules (Huang et al., 2010;
Huppa et al., 2010; Adams et al., 2011; Jiang et al., 2011; Sabatino
et al., 2011). Indeed, the micropipette assay shows that, compared
with transmembrane (TM) CD16a (CD16aTM), CD16aGPI binds faster
and with higher affinity to human and rabbit IgGs but slower and
with lower affinity to murine IgG2a (mIgG2a; Chesla et al., 2000).
Previous study suggests that the membrane anchor influences ligand binding by conformational change of CD16 (Chesla et al.,
2000).
In the study, we further explored the effect of anchor structure of
CD16 on its ligand binding using three different methods to generate soluble CD16s with different anchor structures, allowing us to
isolate the effect of linker segment from the membrane anchor itself
on the intrinsic binding parameters. We also tested how glycosylation of the receptor affected ligand binding, by using tunicamycin
treatment to block the addition of sugar moieties to the protein
core. Our results show that affinity of CD16 binding to hIgG1 correlates with receptor anchor structures, and this correlation is inverted upon switching ligand from hIgG1 to mIgG2a, suggesting
that long-range conformational change on the receptor anchor
could propagate to the ligand binding epitope. Aglycosylated
CD16 has higher affinity for hIgG1 than the glycosylated forms, suggesting an important role of posttranslational modification in regulating receptor binding affinity. Molecular dynamics (MD) simulations show that deglycosylation of CD16 removes the steric
hindrance for CD16–hIgG1 binding, resulting in increased binding
affinity.

RESULTS
Solubilized CD16 captured on microspheres specifically
binds IgG coated on red blood cells
FIGURE 1: Schematics of solubilized CD16 isoforms with different
anchor structures and soluble CD16a–Ig chimera. The extracellular
domains of CD16 are depicted as two Ig-like globules, with the
N-glycosylation sites shown as sticks. An additional glycan is part of
the GPI anchor, which acts as a linker between the C-terminus of the
peptide and the phosphatidylinositol group. The amino acids in
extracellular domains that differ between CD16a and CD16bNA2 are
listed. +*The gained glycosylation site in CD16bNA2 due to the change
D65 → N65.
3450 | N. Jiang, W. Chen, et al.

To test for binding specificity, adhesion frequencies of IgG coated
on red blood cells (RBCs) to solubilized CD16 of different forms and
anchor structures (Figure 1) captured by 214.1 precoated on microspheres were compared with several controls. Adhesion frequencies
were measured with a 2-s contact duration. As exemplified using
microspheres incubated with various CD16 lysates (Figure 2A), the
∼50% adhesion frequencies to hIgG1-coated RBCs were reduced to
∼10% by the anti-CD16 antibody, 3G8. Furthermore, use of microspheres incubated with bovine serum albumin (BSA) instead of
CD16aTM lysate or RBCs not coated with anything (but undergoing
Molecular Biology of the Cell

was then calculated using the following equation (Williams et al.,
2001):
Pa = (Pt – Pn )/(1 – Pn ) 

(1)

The Pa versus t binding curve was fitted by Eq. 2 together with the
separately measured receptor and ligand densities (mr and ml, respectively; Chesla et al., 1998):
Pa = 1 – exp{– mrm1A cK a [1 – exp(– k off t )]}

(2)



to estimate Ka and koff, the 2D affinity (in μm2) and off-rate (in s−1),
respectively. The 2D on-rate can be calculated from kon = Kakoff. The
Ka value is lumped with the contact area Ac in the curve fit, which is
called collectively the effective 2D affinity. We kept Ac constant in all
experiments.

CD16aGPI lysate binds hIgG1 with a higher affinity than
CD16aTM lysate

FIGURE 2: Microspheres bearing CD16 bound RBCs coated with
hIgG1 specifically. (A) Adhesion frequency of CD16 lysate–coated
microspheres to hIgG1-coated RBCs was substantially higher than the
nonspecific adhesions, controlled using a blocking anti-CD16 (3G8) or
microspheres incubated with BSA (instead of lysates of CD16
expressing CHO cells) or RBCs not coated with anything. N.D., not
done. Adhesion frequencies were measured with a 2-s contact
duration. (B) Adhesion frequency vs. contact duration (t) binding
curves. The two sets of data (points) were obtained using RBCs
coated with hIgG1 to contact 214.1-precoated microspheres
incubated with lysates from CHO cells expressing CD16aTM (filled
diamonds) or plain CHO cells (open diamonds). For the former, the
specific adhesion frequency Pa after removing the nonspecific
adhesion frequency (Eq. 1) is shown and fitted by Eq. 2 (curve). Data
are mean ± SEM of five RBC-microsphere pairs with 100 contacts each
per bar or point.

the same CrCl3 procedure except adding IgG) reduced the adhesion frequencies to the background level (∼2%).
The kinetic information is embedded in the curves of adhesion
frequency versus contact duration, as exemplified by the data in
Figure 2B, measured with CD16aTM lysate–coated microspheres and
hIgG1-coated RBCs using seven contact durations, t, from 0.5 to
16 s. Five microsphere–RBC pairs were tested at each contact duration, and 100 contacts were repeated for each pair to calculate a
total adhesion frequency Pt (number of adhesions observed divided
by the 100 contacts). Nonspecific adhesion frequency, Pn, was controlled using the 214.1-coated microspheres incubated with lysates
of plain CHO cells (Figure 2B). The specific adhesion frequency Pa
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Previously we showed that CD16aGPI expressed on CHO cells had a
higher 2D affinity for total human IgG than CHO cell CD16aTM
(Chesla et al., 2000). This result was confirmed by a new set of micropipette experiments (Figure 3A). Here we measured binding frequencies at multiple contact durations and then fitted the data to
Eq. 2 to obtain affinities and off-rates as shown in Figure 2B. We
showed that the differential 2D affinities observed previously using
CHO cell CD16 and total human IgG were preserved despite the
fact that in the new experiments, the CD16a membrane isoforms
were isolated from the cell surface and captured by 214.1 on the
microspheres to interact with hIgG1. The higher AcKa values of solubilized than cell surface receptors may partly be due to a higher Ac
value for the former than the latter because microspheres have a
smoother surface than CHO cells (Wu et al., 2007), resulting in
greater effective contact area for the former than the latter. On the
other hand, CD16aGPI lysate and CD16aTM lysate had comparable
2D off-rates for dissociation from hIgG1 (Figure 3B), consistent with
previous findings for cell-surface CD16a membrane isoforms (Chesla
et al., 2000).

CD16 anchor structure affects 2D binding affinity for hIgG1
The findings that hIgG1 bound with a higher 2D affinity to CD16aGPI
than CD16aTM even after the receptors were captured from the cell
lysates on the microspheres (Figure 3A) exclude differential diffusivities, flexibilities, heights, orientations, and organizations on the
membrane, as well as any other cell-associated factors between the
two isoforms, as possible causes for the affinity difference. We
therefore focused on the structural differences in the membrane anchor per se. We hypothesized that the membrane anchor affects ligand binding by inducing conformational changes in the ligand
binding site (Chesla et al., 2000). Because the membrane anchor is
one Ig domain away from the ligand binding site, the proposed
anchor effect on binding affinity must be exerted allosterically. Perturbing the structure along this allosteric pathway of regulation is
therefore predicted to alter the binding affinity.
To test this hypothesis, we used lysis, phosphatidylinositol-specific phospholipase C (PIPLC) treatment, and spontaneous shedding to obtain different anchor structures of solubilized receptors
from CD16aGPI or CD16bNA2-expressing CHO cells. Lysing the cells
keeps the molecule’s original GPI anchor. PIPLC treatment enzymatically cleaves the diacylglycerol moiety of the GPI anchor. Note
that PIPLC does not affect N-glycans on CD16. Spontaneous shedding results from the action of metalloproteinases bound to the

Anchor and glycosylation effects of CD16
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FIGURE 3: Comparison of 2D affinities (A) and off-rates (B) of
CD16aTM and CD16aGPI for hIgG1. CD16 molecules were expressed
on CHO cell surface or captured on 214.1-precoated microspheres
from CHO cell lysates. Data are presented as mean ± SEM from fitting
Eq. 2 to specific adhesion frequencies measured at multiple contact
durations (for CD16 on CHO cell surface, six contact durations
ranging from 0.25 to 8 s, three RBC–CHO cell pairs with 100 contacts
each per contact duration; for CD16 lysates, seven contact durations
ranging from 0.5 to 16 s, five RBC–microsphere pairs with 100
contacts each per contact duration) as in Figure 2B. Data values are
below the plots; p values from Student’s t test are above the data
bars.

FIGURE 4: Comparisons of 2D affinities of hIgG1 (A) and mIgG2a (B)
for CD16. CD16 molecules are captured on 214.1-precoated
microspheres from CHO cell lysates, supernatants of CHO cells
treated with PIPLC, or supernatants of CHO cells subjected to
shedding treatment. Adhesion frequencies were measured with an 8-s
contact duration and converted to 2D effective affinities using Eq. 3.
Data are mean ± SEM of 5–15 RBC–microsphere pairs with 100
contacts each per bar. Data values are below the plots; p values from
Student’s t test are above data bars.

cell membrane, which produces molecules with only the extracellular domain (Lanier et al., 1989). The micropipette adhesion assay
was applied to measure 2D affinities between hIgG1 and these
molecules at an 8-s contact duration, long enough for the interaction to reach equilibrium (Figure 2B). Specific adhesion frequencies, Pa, were obtained by removing background adhesion frequencies from total adhesion frequencies using Eq. 1 and then
substituting into the following equation to calculate the effective
2D affinities:

the full anchor structure plus cytoplasmic tail (lysate) showed a
much higher affinity for hIgG1 than the molecule with no anchor
(shedding; Figure 4A left). The PIPLC treatment was not used
because PIPLC cannot cleave the polypeptide transmembrane anchor of CD16aTM. Student’s t test confirmed that the
affinity differences within each group of CD16 were significant
(p values in Figure 4A). These results support our hypothesis regarding allosteric regulation of ligand binding affinity by receptor anchor.

A cK a = – ln(1 – Pa )/mrm1 

The anchor effect on ligand binding is inverted when hIgG1
is replaced by mIgG2a

(3)

This equation is a transformation of the equilibrium (i.e., t → ∞)
version of Eq. 2.
Changing the anchor structure of CD16aGPI from full to partial
to none resulted in a progressive decrease in its affinity for
hIgG1 (Figure 4A, middle). The same result was seen with CD16bNA2, also a GPI-anchored molecule (Figure 4A, right). Further
confirmation was obtained using CD16aTM, as the molecule with
3452 | N. Jiang, W. Chen, et al.

The correlation between CD16a anchor structure and its affinity was
inverted when hIgG1 was changed to mIgG2a for all membrane
isoforms of CD16 (CD16aTM, CD16aGPI, and CD16bNA2), such that
for each CD16 membrane isoform, the solubilized receptor from lysates with the full anchor structure had the lowest affinity, that from
shedding with no anchor had the highest affinity, and that cleaved
from PIPLC treatment (for CD16aGPI and CD16bNA2 only) with partial
Molecular Biology of the Cell

FIGURE 5: Effects of tunicamycin treatment on CD16–hIgG1 binding. (A) The 2D affinities and
(B) off-rates of CD16 isoforms expressed on CHO cell-surface and soluble CD16–Ig chimera for
hIgG1 obtained from fitting Eq. 3 to specific adhesion frequencies measured at six contact
durations ranging from 0.25 to 8 s (three RBC–CHO cell or RBC–RBC pairs with 50 or 100
contacts each per contact duration) as in Figure 2B. (C) Representative Scatchard plot analysis
for saturation binding of CLBFcgran-1 to CD16aTM. (D) The 3D affinities of CD16 isoforms
expressed on CHO cell surface for CLBFcgran-1 obtained by Scatchard plot analysis as
illustrated in C. In A, B, and D, data both without and with tunicamycin treatment are presented
as mean ± SEM. Data values are below the plots; p-values from Student’s t test are above data
bars.

GPI anchor had intermediate affinity (Figure 4B). Again, Student’s
t test confirmed the significance of the differences in 2D affinities
(p values in Figure 4B).

Glycosylation of CD16 molecules affects their ligand
binding affinities
The effect of the receptor anchor structure on the ligand binding
affinity may be changed by perturbations in the structure of the ligand binding site, as it resides on the other end of the proposed
allosteric pathway of binding affinity regulation. One possible structure is the glycan attached to Asn-163 of CD16, which is inside the
binding pocket of the CD16–hFc1 complex (Sondermann et al.,
2000; Radaev et al., 2001; Ferrara et al., 2011). We thus prepared
deglycosylated CHO cell CD16 molecules by adding tunicamycin, a
widely used N-glycosylation inhibitor, to culture medium of CD16expressing CHO cells for 40 h. This treatment did not alter CD16
expression significantly, as revealed by fluorescence-activated cell
sorting (FACS; unpublished data). The micropipette adhesion frequency assay was used to estimate 2D affinities and off-rates of
CD16aTM, CD16aGPI, and CD16bNA2 for hIgG1. As expected, for all
three CD16 isoforms, deglycosylation increased their effective 2D
affinities for hIgG1 (Figure 5A). By comparison, the 2D off-rates were
comparable or slightly different between aglycosylated and glycosylated CD16 molecules (Figure 5B).
Volume 27 November 7, 2016

To exclude the possibility that the increase of effective 2D affinities of CD16 for
hIgG1 with tunicamycin treatment was due
to a cellular effect, we measured 2D binding
of a soluble CD16a–Ig chimera for hIgG1. In
agreement with the results of CHO cell
CD16, the effective 2D binding affinity of
hIgG1 was fourfold higher for CD16a–Ig secreted from CHO cells with tunicamycin
treatment than without (Figure 5A, far right),
confirming that the affinity increases in the
cell-surface CD16 for hIgG1 were due to the
change in the receptor molecules. The twoorders-of-magnitude higher effective 2D affinities of hIgG1 for soluble CD16a–Ig than
for CHO cell-surface CD16a, regardless of
whether they were for glycosylated or deglycosylated molecules, are consistent with the
increase by one to two orders of magnitude
in effective 2D affinities of hIgG1 for CD16a
lysates on microspheres (Figure 3A); both
can be explained by the increases in effective contact area, Ac. This is consistent with
our previous report that CD16bNA2 reconstituted on RBCs has a ∼50-fold-higher effective 2D affinity for hIgG than the same CD16bNA2 reconstituted or transfected on CHO
cells (Williams et al., 2001).
Finally, we measured 3D affinities of an
anti-CD16 monoclonal antibody (mAb;
CLBFcgran-1) for different CD16 isoforms
using saturation binding experiments and
Scatchard plot analysis (Figure 5C). Consistently, deglycosylation also increased the 3D
affinity of CLBFcgran-1 for CD16 (Figure 5D).
These results support our hypothesis that
glycosylation perturbs the structure of CD16.

Deglycosylation of CD16 enhances CD16–hFc1 binding
To understand the structural basis for the effects of CD16 glycosylation on its ligand binding, we performed all-atom, explicit-solvent
MD simulations for both glycosylated and aglycosylated CD16a liganded with hFc1, which contains two glycans on Asn-297. The starting structure of the simulation of the glycosylated CD16a-hFc1 complex was a crystal structure (Protein Data Bank 3SGJ; Ferrara et al.,
2011) in which two N-glycans are attached to Asn-46 and Asn-163.
The starting structure of the aglycosylated CD16a-hFc1 complex was
obtained by removing in silico the glycans of CD16a in the crystal
structure. After 10 ns in the simulations, the root mean square deviations of the Cα atoms of the complexes reached a plateau, suggesting that the systems were equilibrated (Supplemental Figure S1). The
40-ns period after equilibration was used for further analysis.
To measure how glycosylation of CD16 affects the binding, we
calculated the contact times of interaction for residue pairs between
hFc1 and CD16. Two residues are defined as in contact if any pair of
their heavy atoms of side chains (Cα atom for glycine) are within
4.5 Å. Then the contact time is calculated as the fraction of the total
time that the two residues are in contact. The difference in contact
time between the aglycosylated and glycosylated complexes is
shown in Figure 6. Positive or negative value indicates that the interaction is strengthened or weakened upon deglycosylation, respectively. Some interactions between the N-terminal loops of hFc1 and
Anchor and glycosylation effects of CD16
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another important means for Fc receptors to
modulate their ligand binding affinities. In
addition, results from our MD simulations
suggest a structural basis for deglycosylation
to increase the ligand binding affinity.
A significant new finding of the present
work is the preservation of the previously
observed anchor effect (Chesla et al., 2000)
after replacement of the CD16-expressing
CHO cells by solubilized CD16-bearing microspheres (Figure 3). A concern for using
solubilized CD16 is that the exposed membrane anchor could induce nonspecific interactions. To test this possibility, we used
an anti-CD16 antibody, 3G8, to block the
CD16–IgG binding. The binding was reduced by fourfold to fivefold (Figure 2A),
indicating that the nonspecific binding due
to exposed anchor is negligible. Also note
that the same mAb (214.1) was used to capture different solubilized CD16 molecules,
therefore presenting the same molecular
segment to the IgG ligand for binding. In
spite of this, changing the anchor structure,
which represents a molecular segment extending away from the 214.1 capture point
on the other side of the ligand binding site,
still affects ligand binding affinity (Figure 4).
This allows us to rule out the differential diffusivities, flexibilities, heights, orientations,
and organizations on the membrane, as well
FIGURE 6: Deglycosylation of CD16 enhances the CD16-hFc1 binding. (A) Difference in contact
as any other cell-associated factors of these
time between aglycosylated and glycosylated CD16-hFc1 complexes for residue pairs that
molecules, as possible causes for the obinteract between chain A of hFc1 and CD16. Two residues are defined as in contact if any pair of
served anchor effects.
their heavy atoms of side chains (Cα atom for glycine) are within 4.5 Å distance. Then the
Another important new finding is the
contact time is calculated as the fraction of the total time that the two residues are in contact.
preservation of the ligand specificity of the
(B) Difference in contact time between aglycosylated and glycosylated CD16-hFc1 complexes
anchor effect, such that the changes of affinfor residue pairs that interact between chain B of hFc1 and CD16. In A and B, only pairs with
>0.1 absolute difference are shown. The calculations were done on the last 40 ns of the
ity of CD16 for hIgG1 with changes of ansimulations, with one snapshot per 10 ps. (C) Structure of the glycosylated CD16–hFc1 complex
chor structure are opposite to that for
(PDB 3SGJ). Chains A and B of hFc1 are shown in pink and gray, respectively. CD16 is in green.
mIgG2a: CD16 with full membrane anchor
Sticks represent glycans attached to proteins. Red spheres show residues whose interactions
has highest affinity for hIgG1 but lowest afstrengthened upon deglycosylation; blue spheres show residues whose interactions weakened.
finity for mIgG2a, whereas CD16 without anchor has the lowest affinity for hIgG1 but the
highest affinity for mIgG2a (Figure 4). The observation further supCD16 are weakened (blue spheres in Figure 6C). However, more
ports that the anchor effect is caused by CD16 itself rather than its
interactions between the CH2 domain of hFc1 and CD16 are
cellular environment. To dissect the ligand specificity of the anchor
strengthened (red spheres in Figure 6C). Of interest, the strengtheffect, we compared the amino acid sequences of hIgG1 and mIgG2a
ened interactions are mostly located near the glycan at Asn-163 of
(Supplemental Figure S2). The two sequences are highly conserved,
CD16 (green sticks in Figure 6C). This result suggests that deglycowith >60% identity. However, in the regions directly interacting with
sylation of CD16 clears the steric hindrance for the CD16–hFc1
CD16, three residues are different. As in the CD16–hIgG1 complex
binding.
structure, His-268 and Glu-269 of the hFc1 B chain interact with LysDISCUSSION
132 of CD16 (Supplemental Figure S3). His-268 and Glu-269 are
changed to Glu and Asp, respectively, in mIgG2a. This change inThe Fc portions of antibodies can modulate immune responses
creases the negative charge of IgG and thus may strengthen the inthrough their interactions with Fc receptors. Different Fc receptors
teraction with Lys-132 of CD16. Moreover, Ala-327 of the hFc1 B
have different cell-specific expression patterns, signaling mechanisms, and ligand binding affinities, which enable specific cellular
chain is in contact with His-135/136. When Ala-327 is replaced by
Asp in mIgG2a, additional attractive electrostatic interactions are exfunctions (Nimmerjahn and Ravetch, 2010). Previously we showed
pected between Asp-327 and His-135/136. Therefore both changes
that different membrane anchor forms (TM vs. GPI) of the same
in the binding interface increase interactions between IgG and CD16,
FcγRIII molecule could modulate their ligand binding affinities (Chesla
et al., 2000). Here we extended this work by showing that the anwhich may contribute to the higher affinity of mIgG2a for CD16 than
chor structure of CD16 affects the ligand binding affinity even in an
hIgG1. Note that the CD16 in the complex crystal structure is a soluble form, that is, it does not have an anchor and corresponds to the
acellular system. We also demonstrated that glycosylation provides
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shedding form used in our micropipette experiments. We speculate
that the binding interface is changed through an allosteric mechanism when CD16 has an anchor, and the change depends on the
anchor form. For the PIPLC-cleaved form of CD16, the interacting
residues between CD16 and IgG may all be conserved between
hIgG1 and mIgG2a, so that their affinities for CD16 are similar. However, for CD16 with a full anchor, other, nonconserved residues may
interact with CD16, and these interactions are favored for hIgG1, so
that hIgG1 has higher affinity for CD16 than mIgG2a.
Although our findings may seem surprising, many examples of
allosteric regulation of ligand binding have been reported. In interactions between selectins and ligands (Lou et al., 2006; Lou and
Zhu, 2007), between platelet glycoprotein Ibα and von Willebrand
factor (Yago et al., 2008), and between bacterial FimH receptor and
mannose ligand (Le Trong et al., 2010), force-induced conformational changes may give rise to catch bonds (Dembo et al., 1988;
Marshall et al., 2003). In integrins, allosteric conformational changes
are related to inside-out and outside-in signaling (Luo et al., 2007)
and may cause catch bonds (Kong et al., 2009; Chen et al., 2010,
2012; Xiang et al., 2011). Closer to our findings, the GPI-anchored
protein Thy-1 has been shown to lose reactivity with several mAbs
and a polyclonal antibody after anchor cleavage by phospholipase
C, indicating that the GPI anchor affects the protein conformation
(Barboni et al., 1995; Kukulansky et al., 1999).
Notwithstanding the foregoing examples, that truncating the
membrane anchor of a receptor may affect its ligand binding has
been underappreciated. It is a common practice to make recombinant soluble receptors with membrane anchors truncated and replaced by different tags for purification by affinity chromatography.
Almost all structural determinations of extracellular domains of cell
surface receptors by crystallography and nuclear magnetic resonance use molecules made in this way. Molecules so made are also
widely used for kinetics measurements by SPR (Galon et al., 1997;
Maenaka et al., 2001; Li et al., 2007). It is an implicit but usually untested assumption that the soluble receptors have identical structures and ligand binding properties as the native molecules on the
cell membrane. This assumption has been challenged by work revealing drastic differences between 3D kinetics of TCR-pMHC binding measured by SPR using soluble molecules and 2D kinetics of the
same interactions measured in situ with cell surface molecules
(Huang et al., 2010; Huppa et al., 2010; Adams et al., 2011; Jiang
et al., 2011; Sabatino et al., 2011). The findings of the present work
also serve as reminder for caution to investigators who use soluble
molecules for structural and functional studies.
To obtain direct evidence for propagation of conformational
changes from the membrane anchor to the ligand binding site may
require structural comparison among CD16 molecules with different
anchor structures, which are currently not available. We reasoned
that perturbing the structures that display the conformational
changes at the ligand binding site might alter the ligand-specific
binding affinity. We chose the N-glycan attached to Asn-163 of
CD16, which resides in the binding pocket of the CD16–hFc1 complex (Sondermann et al., 2000; Radaev et al., 2001; Ferrara et al.,
2011). Targeting glycosylation also has interest in its own right because a substantial number of the recombinant soluble receptors
used in structure determination and SPR measurements are produced in aglycosylated forms by E. coli (Sondermann et al., 2000;
Maenaka et al., 2001; Radaev et al., 2001). It is also an implicit but
usually untested assumption that the aglycosylated receptors have
identical structures and ligand binding properties as the native (and
often glycosylated) molecules on the cell membrane. Using tunicamycin to deglycosylate CHO cell CD16 isoforms, we found about
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threefold increase in the effective 2D binding affinity. This is consistent with the observation that wild-type CD16bNA1-transfected cells
treated with tunicamycin exhibit increased binding of monomeric
IgG (Drescher et al., 2003). Of interest, tunicamycin treatment also
increases the binding of another Fc receptor, FcαR (CD89), to IgA
(Xue et al., 2010). It may be a common property that deglycosylation of FcR causes increased binding of Ig. Of greater interest, deglycosylation of one N-glycosylation site among others, Asn-163 of
CD16 or Asn-58 of CD89, contributes most to the increase of the
respective binding to IgG or IgA (Drescher et al., 2003; Xue et al.,
2010). In fact, Asn-163 of CD16 and Asn-58 of CD89 are located in
the binding interfaces of the CD16–IgG (Sondermann et al., 2000;
Radaev et al., 2001; Ferrara et al., 2011) and CD89–IgA complexes
(Herr et al., 2003), respectively.
Two previous SPR studies reported similar 3D affinities but drastically different kinetics for hIgG1 of recombinant aglycosylated soluble CD16bNA2 containing the extracellular region of the receptor
(Galon et al., 1997; Maenaka et al., 2001). The off-rate measured in
this work is similar to that found by Maenaka et al. (2001). On the
other hand, Galon et al. (1997) reported similar 3D affinities for both
glycosylated and aglycosylated soluble CD16bNA2, contradicting
our finding that glycosylated and aglycosylated CD16 have different
2D affinities for hIgG1. This contradiction highlights the intrinsic difference between 2D and 3D binding, which is also observed in the
binding between TCR and pMHC ligands (Huang et al., 2010). The
difference in 2D affinity of CD16 for IgG is only severalfold among
natural forms of CD16 (TM vs. GPI and glycosylated vs. deglycosylated), in contrast to several orders of difference in 2D affinity of TCR
for different pMHC ligands. However, in the physiological situation
in which CD16 on cell surface binds a large array of IgG on an immune complex, the difference in 2D affinity can be substantially amplified to a large difference in 2D avidity. Therefore we believe that
the difference in 2D affinity of the CD16-IgG binding has a large
effect on the binding of CD16 to immune complexes. In vivo, the
change of the CD16–IgG binding affinity by posttranslational modification of CD16 such as glycosylation may be a way to regulate
immune responses. In fact, CD16 encoded by the same gene could
undergo differential cell type–specific glycosylation (Edberg and
Kimberly, 1997; Drescher et al., 2003), and so the CD16-expressing
cells may be selectively activated in an immune response. The
importance of posttranslational processes is also observed in other
molecular systems, such as CD8, for which nonsialylated glycoforms
are present in immature thymocytes but virtually absent in mature
thymocytes. This glycosylation difference is linked to the difference
in ligand binding affinity between CD8 on mature and immature
thymocytes (Moody et al., 2003).
Our MD simulations suggest that deglycosylation at Asn-163 of
CD16 removes the steric hindrance for the CD16–hFc1 binding and
therefore enhances the binding affinity (Figure 6). This provides a
structural explanation for the glycosylation effects on the CD16–IgG
binding shown by us (Figure 5) and others (Drescher et al., 2003).
In summary, we explored the effect of anchor structure and glycosylation of CD16 on ligand binding using three different methods
to solubilize CD16 molecules with distinct anchor forms. The results
extended our previous study (Chesla et al., 2000) and showed that
the membrane anchor structure itself and glycosylation can regulate
allosterically these intrinsic binding parameters.

MATERIALS AND METHODS
Cells and antibodies
Transfected CHO cells expressing human CD16aTM, CD16aGPI, and
CD16bNA2, as well as untransfected control CHO cells, were cultured
Anchor and glycosylation effects of CD16
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as described previously (Chesla et al., 1998, 2000). The expressions
of various forms of CD16s were periodically checked with flow cytometry. The anti-CD16 nonblocking mAb 214.1 (murine IgG1; Fleit
et al., 1992) was a generous gift from Howard Fleit (State University
of New York, Stony Brook, NY). The anti-CD16 adhesion blockade
mAb CLBFcgran-1 and 3G8 were purified from hybridomas (Selvaraj
et al., 1988). HIgG1 was kindly provided by Adrian Whitty (Biogen,
Boston, MA) and was purchased from Sigma-Aldrich (St. Louis, MO).
Fluorescein isothiocyanate–labeled goat anti-human Fc-specific and
goat anti-mouse Fc-specific antibodies (Sigma-Aldrich) and phycoerythrin (PE)-labeled goat anti-human Fc-specific and goat antimouse Fc-specific antibodies (Jackson ImmunoResearch Laboratories, West Grove, PA) were used to estimate the site density of
hIgG1, CLBFcgran-1, and mIgG2a. The mouse anti-human IgG Fc
mAb 7QD was purchased from General Bioscience (Brisbane, CA).

Preparation of solubilized CD16 and soluble CD16a–Ig
chimera
One gram of each CD16-expressing CHO cell pellet was resuspended in lysis buffer containing 1% Triton X-100 and protease
inhibitors and incubated for 30 min at 4°C (Nagarajan et al.,
1995a). Protease inhibitors included the serine protease inhibitors
phenylmethylsulfonyl fluoride (1 mM) and aprotinin (5 mg/ml) and
the cysteine protease inhibitor iodoacetamide (1 mM). The lysate
was clarified by centrifugation at 100,000 × g for 1 h at 4°C. Supernatant was collected and stored at –80°C for further use. For
CD16b and CD16aGPI, 1% octyl glucoside was added to lyse the
cells and preserve the GPI anchor. To prepare PIPLC cleavage of
GPI-anchored CD16, 107 cells were incubated in 1 ml phosphatebuffered saline (PBS)/5 mM EDTA, pH 7.4, with 0.2 unit of PIPLC
for 1 h at 37°C. To prepare shed CD16, 107 CD16-expressing CHO
cells were incubated in 1 ml of Hanks balanced salt solution at
37°C for 3 h with gentle mixing. The CD16 molecules so generated
are schematically shown in Figure 1 in different forms as labeled by
lysate, PIPLC, and shedding. CD16a–Ig chimera was generated as
described (Li et al., 2002) and is also depicted in Figure 1. Briefly,
the chimeric CD16a–Ig cDNA was transfected into CHO cells,
which were then cultured using CHO serum-free medium. The culture supernatant was collected, and CD16a-Ig was purified using a
Sepharose protein G column by affinity chromatography.

Generation of CHO cells expressing aglycosylated CD16
Tunicamycin blocks N-glycosylation synthesis by inhibiting the
transfer of N-acetylgucosamine-1-phosphate to dolicholmonophosphate. At high concentrations, tunicamycin treatment drastically reduces the expression level of CD16. Twofold serial dilution
of tunicamycin was performed to determine the optimal concentration (78 ng/ml) that blocks the glycosylation of CD16 and yet does
not significantly alter its expression level. CHO cells transfected to
express cell-surface CD16 or CD16a-Ig were rinsed three times using culture medium containing 78 ng/ml tunicamycin (Sigma-Aldrich) and cultured in the same medium for 40 h at 37°C. Cells expressing CD16 membrane isoforms were then rinsed three times
with clean culture medium, detached, and analyzed by FACS for
CD16 expression or by micropipette for IgG binding. Supernatant
from the CD16a-Ig–expressing cell culture was collected, and
CD16a–Ig was purified using Sepharose protein G column by affinity chromatography.

Coupling of capturing antibody to microspheres
After being washed twice in carbonate buffer, 10 million carboxylated microspheres were washed three times in phosphate buffer
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(pH 4.5) and resuspended in 120 μl of phosphate buffer. The same
volume of 2% carbodiimide solution was added dropwise to the
microsphere suspension, and the mixture was incubated for 3–4 h
at room temperature with agitation. Unreacted carbodiimide was
removed by three washes with phosphate buffer and resuspended
in 200 μl of borate buffer. Next 20–40 μg of 214.1 or 7QD was
added to the microsphere mixture and incubated overnight at
room temperature with mixing. Microspheres were collected, and
the antibody concentration in the supernatant was tested by the
Micro BCA Protein Assay Kit (Pierce Biotechnology, Rockford, IL) to
estimate the efficiency of coupling. The pellet was resuspended in
0.2 M borate buffer, and 50 μl of 0.1 M methanolamine was added
and mixed gently for 30 min at room temperature to block unreacted sites on the microspheres. Microspheres were then incubated in 10 mg/ml BSA solution for 30 min at room temperature.
Finally, microspheres were collected and stored in PBS with 1%
BSA at 4°C for future use.

Chromium chloride coupling of antibody to RBCs
HIgG1, mIgG2a, or F(ab′)2 of mAb 7QD was covalently coupled to
the membranes of RBCs using a previously described CrCl3 method
(Chesla et al., 1998). A 1% CrCl3 solution was prepared, properly
aged at pH 5, and diluted in 20 mM acetate-buffered saline, pH 5.5,
at ratios ranging from 1:6700 to 1:17,000. Fresh RBCs were washed
five times in saline and resuspended to 2% hematocrit. IgG was
added to each 250-μl sample and mixed. An equal volume of diluted CrCl3 solution was added dropwise with constant agitation.
After 5 min, the reaction was stopped by addition of 0.5 ml PBS/5
mM EDTA/1% BSA. Cells were subsequently washed and stored in
EAS45 as described previously (Dumaswala et al., 1996). An aliquot
from each sample was examined under light microscopy for aggregation. Samples were assayed for coating density and uniformity by
flow cytometry.

Site-density determination
Site densities of proteins on RBCs (CrCl3-coupled IgG or soluble
CD16–Ig captured by precoated 7QD) and microspheres (solubilized CD16 captured by precoated 214.1) were determined by
quantitative fluorescence immunoassay (Chesla et al., 1998,
2000; Williams et al., 2000a,b, 2001; Shashidharamurthy et al.,
2009). Samples were prepared for flow cytometry as described
(Chesla et al., 2000). The mean fluorescence intensities of the
RBCs or microspheres were compared with standard calibration
beads (Bangs Laboratories, Fishers, IN, and Becton Dickinson,
San Jose, CA) to determine the mean number of fluorophores
per cell or microsphere, which was then converted into labeled
protein per cell.

Micropipette adhesion frequency assay
Two-dimensional affinities and kinetic rates of CD16 for IgG were
measured by the micropipette adhesion frequency assay as previously described (Chesla et al., 1998). Briefly, 103 CHO cells expressing membrane CD16, microspheres captured with solubilized CD16,
or RBCs captured with CD16–Ig and 104 ligand-coated RBCs were
respectively added to separate corners of a cell chamber sufficiently
far apart to avoid mixing. The cell chamber was filled with RPMI
(Mediatech, Manassas, VA) plus 1% BSA, 5 mM EDTA, and 0.04%
sodium azide and mounted on the stage of an inverted microscope
(Axiovert 100; Zeiss, Oberkochen, Germany). A single CD16-bearing CHO cell, microsphere, or RBC and a single IgG-coated RBC
were respectively aspirated by two apposing micropipettes and
aligned via micromanipulation. One pipette was mounted to a
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computer-driven piezoelectric translator to move the two cells into
contact for a predetermined area and duration. On pipette retraction, the two cells were either immediately separated (i.e., no adhesion, scored 0) or remained bound, which stretched the RBC for a
short time before it was detached by force (i.e., adhesion, scored 1).
This adhesion test cycle was repeated 100 times to estimate adhesion frequency, and three or five pairs of cells were used to obtain a
mean and SEM of adhesion frequency for each contact duration,
which was varied from 0.5 to 16 s.

Antibody saturation binding experiment
The affinities of the anti-CD16 mAb CLBFcgran-1 for CD16 isoforms
expressed on CHO cells were measured by saturation binding with
twofold serial dilution. CLBFcgran-1 at varying concentrations was
incubated with CD16-expressing cells for 30 min in triplicate wells
containing FACS buffer. Cells were then washed and stained with
PE-conjugated goat anti-mouse Fc specific antibody for an additional 30 min. Cells were washed, and the expression of CD16 was
checked via flow cytometry. Controls were performed both with no
staining and with secondary antibody staining alone without
CLBFcgran-1.

Molecular dynamics simulation
The starting structure for the glycosylated CD16-hFc1 complex
was the published cocrystal structure downloaded from the Protein Data Bank (PDB code 3SGJ; Ferrara et al., 2011). The starting
structure for the aglycosylated CD16-hFc1 complex was obtained
by removing in silico the glycans on CD16 in the crystal structure.
The simulation systems were prepared using LEaP in AmberTools14 (Case et al., 2014). The Amber ff12SB (Maier et al., 2015)
and GLYCAM06 (Kirschner et al., 2008) force fields were used for
proteins and glycans, respectively. Each starting structure was
placed into a truncated octahedral periodic box of TIP3P water
molecules with a 15-Å minimal distance between the edges of the
water box and the solute. Sodium and chloride ions were added to
neutralize the systems and produce a 150 mM ionic strength. MD
simulations were performed using NAMD (Phillips et al., 2005).
The particle mesh Ewald method (Darden et al., 1993) was used to
treat long-range electrostatic interactions. The cutoff for nonbonded interactions was set to 12 Å, with a switching function
starting from 10 Å. SHAKE (Ryckaert et al., 1977) was used to constrain lengths of bonds involving hydrogen. Time-step was 2 fs.
The systems were energy minimized using the conjugate gradient
method in two steps: first with heavy atoms of the proteins fixed,
and then with heavy atoms of the proteins harmonically restrained
(force constants of 5 kcal/mol Å2). After minimization, the systems
were gradually heated from 0 to 310 K during 120-ps canonical
ensemble (NVT)-MD simulations with harmonic restraints (force
constants of 5 kcal/mol Å2) on heavy atoms of the proteins. Subsequent isothermal isobaric ensemble (NPT)-MD simulations were
performed for 5 ns with the same harmonic restraints. Then the
harmonic restraints were reduced to zero in four steps with respective force constants of 1, 0.1, 0.01, and 0 kcal/mol Å2. Each step
contains a 1-ns NPT-MD simulation. Finally, NPT-MD production
simulations were performed for 50 ns each. The simulations were
run on XSEDE (Towns et al., 2014).
VMD (Humphrey et al., 1996) and PyMOL (version 1.7) were used
for visualization and analysis. Two residues were defined as in contact if any pair of their heavy atoms of side chains (Cα atom for glycine) were within 4.5 Å. Then the contact time was calculated as
fraction of total time the two residues were in contact. Only the last
40 ns was used to calculate contact time.
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